1 min read
Add as a preferred source on Google

Evotec Announces Second FDA IND Acceptance in Bristol Myers Partnership

The Nov. 19 acceptance advances the strategic protein degradation partnership; the candidate was not identified.

A sealed vial stands beside a microscope in a research laboratory / TokenPost.ai
A sealed vial stands beside a microscope in a research laboratory / TokenPost.ai

Evotec announced that its strategic protein degradation partnership with Bristol Myers Squibb received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration on Nov. 19, 2026.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…